Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy of Lutikizumab in Adults with Moderate to Severe Hidradenitis Suppurativa Following Inadequate Response to Anti-TNF Therapy: A Phase Study

  • By

  • Alexa B. Kimball

  • Konrad T. Sawicki

  • Lindsay Ackerman

  • Hermenio Lima

  • Evangelos J. Giamarellos-Bourboulis

  • Tianyu Zhan

  • Leonidas Drogaris

  • Yihua Gu

  • Christine M. Lee

  • Mona Akbari

  • David A. Williams

  • Falk G. Bechara

  • May 1, 2026

Share

Objective:

To assess the clinical efficacy and safety of lutikizumab in adults with moderate to severe hidradenitis suppurativa (HS) who have experienced inadequate response to anti-TNF therapy.

Key Findings:
  • Lutikizumab demonstrated a significant reduction in total abscess and inflammatory nodule count compared to placebo.
  • The treatment was well tolerated with a safety profile consistent with previous studies.
Interpretation:

Dual blockade of IL-1α and IL-1β with lutikizumab may provide an effective therapeutic option for patients with HS who do not respond to existing anti-TNF therapies.

Limitations:
  • The study was limited to a specific population and may not generalize to all HS patients.
  • Short follow-up period may not capture long-term efficacy and safety.
Conclusion:

Lutikizumab shows promise as a new treatment option for moderate to severe HS, particularly in patients with inadequate response to anti-TNF therapies.

Original Source(s)

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase

  • by Alexa B. Kimball, Konrad T. Sawicki, Lindsay Ackerman, Hermenio Lima, Evangelos J. Giamarellos-Bourboulis, Tianyu Zhan, Leonidas Drogaris, Yihua Gu, Christine M. Lee, Mona Akbari, David A. Williams, Falk G. Bechara

  • May 1, 2026

Related Content

Modalities of Combined Medical and Surgical Treatment in Hidradenitis Suppurativa: A Systematic Review of Efficacy and Safety

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis